Literature DB >> 2869677

Effect of beta blockade on silent regional left ventricular wall motion abnormalities.

P F Cohn, E J Brown, R Swinford, H L Atkins.   

Abstract

The effect of beta-adrenergic blockade on regional left ventricular wall motion abnormalities was studied in 11 patients with coronary artery disease and silent myocardial ischemia during exercise testing. Four patients were asymptomatic; 7 were asymptomatic after a myocardial infarction. Left ventricular wall motion abnormalities were characterized by reduced regional ejection fraction (EF) during exercise determined by gated left anterior oblique images of the cardiac blood pool. In the 11 patients, 10 anteroseptal and 8 inferoposterior regions were subserved by stenotic coronary arteries. Before beta blockade, regional EF decreased in 15 of 18 regions. After beta blockade, this occurred in only 6 of 18 regions (p less than 0.05); the other 12 regions showed no change or an actual increase in regional EF. Thus, beta-adrenergic blockade effectively improved the reduction in exercise regional EF usually seen in patients with coronary artery disease with silent myocardial ischemia. One probable mechanism of action is a reduction in myocardial oxygen requirement at peak exercise.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2869677     DOI: 10.1016/0002-9149(86)90828-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

Review 1.  Silent myocardial ischaemia. Implications for therapy.

Authors:  N G Uren; D P Lipkin
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

Review 2.  Profile of an ideal antianginal agent.

Authors:  E J Lazar; W H Frishman
Journal:  Drugs       Date:  1989       Impact factor: 9.546

Review 3.  Indications for treatment of silent myocardial ischemia.

Authors:  P F Cohn
Journal:  Cardiovasc Drugs Ther       Date:  1988-05       Impact factor: 3.727

Review 4.  Beta receptor antagonists in the treatment of heart failure.

Authors:  H Persson; L Erhardt
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.